¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chemotherapeutic drug monitoring"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® fetal monitoring ÇÑ±Û Å¾ư¨½Ã
¼³¸í   
  ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀǠžÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» Å¾ư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü Å¾ư¨½Ã¿Í ºÐ¸¸Áߠžư¨½Ã·Î Å©°Ô ³ª´«´Ù.
  
  1. ºÐ¸¸Àü Å¾ư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀǠžÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù.
  
    1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼­ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼­ ¾ç¼ö¸¦ ¾ò¾î¼­ ºÐ¼®ÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼­ ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù.
  
    2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼­ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼­ ±×°÷ÀÇ Ç÷°üÀ» Ã£¾Æ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»çÇϴ ¹æ¹ý.
  
    3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼­ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î Å¾ư¡ Àڱüӿ¡¼­ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â Å¾ÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. Å¾ÆÀÇ ¿îµ¿°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ Å¾ÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù.
  
    4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ Å¾ƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼­ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ Å¾ư¡ ¹ÝÀÀÀ» Çؼ­ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù.
  
    5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» Çؼ­ ½É¹Ú¼ö°¡ º¯È­ÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀÌ´Ù.
  
  2. ºÐ¸¸Áߠžư¨½Ã
  
  ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ °Ç°­»óŸ¦ °¨½ÃÇϴ °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ Å¾ư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀǠžư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù.
  
    1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù.
  
    2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼­ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼­ Å¾ÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁַΠ°Ë»ç¸¦ ÇàÇϴ Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù.
¿µ¹® antihypertensive drug ÇÑ±Û °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
¼³¸í   
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇϸ砳ôÀº Ç÷¾ÐÀ» ³·Ãߴ ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃ۴ Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀǠȰµ¿À» ¾îµð¼±°¡ Â÷´ÜÇϴ ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù.
¿µ¹® antimalarial drug ÇÑ±Û ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
¼³¸í   
  ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Å°´Ï³×, Å¬·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼­ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼­ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ À־ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼­ÀǠȯ»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇϴ °Í(Ç×¹ø½Äü ¾àÀº Å¬·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Å¬·Î·Î±¸¾Æ³ªÀ̵å, Å°´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦Çϴ °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×À̴ °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇѠŸÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ È¯ÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯È­ÇÏÁö ¾Ê´Â´Ù.
¿µ¹® drug ÇÑ±Û ¾à, ¾à¹°, ¾àÁ¦
¼³¸í   
  1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½Ã۴ °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â È­ÇÕ¹°. ¾à¸®Çп¡¼­´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â È­Çй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °­ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼­·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ­, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, Ã¼Áß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ­´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í Àִ ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à.
¿µ¹® drug resistance ÇÑ±Û ¾à¹°³»¼º
¼³¸í   
  1. È­Çпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ È­Çпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼­ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈ­µÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ Àִ ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ Àִ ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇϸ頳»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼­ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇϴ °Í µîÀÌ ±× ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • chemotherapeutic
    1. È­Çпä¹ý- 2. È­Çпä¹ýÁ¦
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦
  • chemotherapeutic index
    È­Çпä¹ýÁö¼ö
  • area monitoring
    ±¸¿ª°¨½Ã
  • air monitoring
    ´ë±â°¨½Ã
  • blood glucose monitoring
    Ç÷´ç°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • fetal monitoring
    žư¨½Ã, žƸð´ÏÅ͸µ
  • hemodynamic monitoring
    Ç÷¿ªÇа¨½Ã, Ç÷¿ªÇиð´ÏÅ͸µ
  • invasive monitoring
    ħ½À°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • intraoperative monitoring
    ¼ö¼úÁß°¨½Ã
  • monitoring
    °¨½Ã, ¸ð´ÏÅ͸µ
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • monitoring
    °¨½Ã
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦
  • chemotherapeutic
    È­Çпä¹ý-, È­Çпä¹ýÁ¦
  • chemotherapeutic index
    È­Çпä¹ýÁö¼ö
  • air monitoring
    ´ë±â°¨½Ã
  • area monitoring
    ±¸¿ª°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • fetal monitoring
    žư¨½Ã
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • intraoperative monitoring
    ¼ö¼úÁß°¨½Ã
  • invasive monitoring
    ħ½À°¨½Ã
  • monitoring
    °¨½Ã
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • OTC drug : over-the-counter drug
    ÀϹݸžà.
  • air monitoring
    ´ë±â¿À¿°°¨½Ã(ËÀË»ËçËç˧Ëà).
  • area monitoring
    ±¸¿ª<¹æ»çÇÇÆø>°¨½Ã.
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • personal monitoring
    °³ÀÎ (ÇÇÆø)°¨½Ã
  • personal monitoring
    °³Àμ±·®°¨½Ã
  • quality monitoring
    Á¤µµ°ü¸®°¨½Ã
  • radiation monitoring
    ¹æ»ç¼±°¨½Ã
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • IND : investigational new drug
    ½ÃÇè¿ë½Å¾à.
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • NDA : new drug application
    ½Å¾àÇã°¡½Åû.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • therapeutic drug monitoring
    Ä¡·áÀû ¾àÁ¦°¨½Ã
  • therapeutic drug monitoring
    Ä¡·áÀû ¾à¹°³óµµ ¸ð´ÏÅ͸µ, Ä¡·áÀû ¾à¹°³óµµ ÃøÁ¤.
  • chemotherapeutic
    È­Çпä¹ý(¼º)ÀÇ
  • chemotherapeutic
    È­Çпä¹ý(¡­èþÛö)¼º (ÀÇ), È­Çпä¹ýÁ¦.
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦
  • chemotherapeutic index
    È­Çпä¹ýÁö¼ö(¡­ò¦â¦).
  • drug dependence ; drug dependency
    ¾à¹°ÀÇÁ¸(¼º).
  • air monitoring
    ´ë±â¿À¿°°¨½Ã(ËÀË»ËçËç˧Ëà).
  • area monitoring
    ±¸¿ª<¹æ»çÇÇÆø>°¨½Ã.
  • behavior monitoring program
    Çൿ(ÇàÅÂ)°¨½ÃÇÁ·Î±×·¥
  • fetal monitoring
    žư¨½Ã.
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    ¾Æ¸Þ¹Ù±¸ÃæÁ¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦(ûùùÊÖûÛöð¥)
  • selected ion monitoring
    ¼±ÅÃ(àÔ÷É) À̿ ¸ð´ÏÅ͹ý(Ûö)
  • single-ion monitoring
    ´Ü(Ó¤)À̿ ¸ð´ÏÅ͸µ
  • drug-detoxication enzyme
    ¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
  • drug-metbolizing enzyme
    ¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
  • drug resistance
    ¾à¹° ÀúÇ×(å·Úªî½ù÷)
  • drug-resistance plasmid
    ¾à¹°ÀúÇ×(å·Úªî½ù÷) Çö󽺹̵å (ÔÒ) R plasmid
  • narcotic drug
    ¸¶¾à(ئå·)
  • psychedelic drug
    ȯ°¢Á¦(ü³ÊÆð¥)
  • radiomimetic drug
    ¹æ»ç¼± ¾ç(À¯»ç) ¾à¹°(Û¯ÞÒàÊåÆ(ëºÞÄ)å·Úª)
  • sulfa drug
    ¼³ÆÄÁ¦(ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦
  • monitoring
    °¨½Ã
  • personal monitoring
    °³ÀÎ(ÇÇÆø)°¨½Ã
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • drug abuse
    ¾à¹°³²¿ë
  • narcotic drug
    ¸¶¾à
  • tuberculostatic drug
    Ç×°áÇÙ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
DA dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis...
CHDM comprehensive hospital drug monitoring
DRMS drug reaction monitoring system
PDMS patient data management system; pharmacokinetic drug monitoring service; polydimethylsiloxane
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TDM Therapeutic Drug Monitoring
ABPM Ambulatory BP monitoring
ABPM Ambulatory Blood Pressure Monitoring
AEM Ambulatory Electrocardiographic Monitoring
AIMS Australian Incident Monitoring Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chemotherapeutic agent
    È­ÇÐ ¿ä¹ýÁ¦
  • chemotherapeutic index
    È­ÇÐ ¿ä¹ý Áö¼ö
  • ambulatory ventricular function monitoring
    º¸Çà ½Ã ½É½Ç±â´É °¨½Ã
  • length monitoring system
    ±æÀÌ °¨Áö°è
  • monitoring device
    °¨½Ã ÀåÄ¡
  • monitoring instrument
    °¨½Ã ±â±¸
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
  • antagonistic drug
    ±æÇ× ¾à, ±æÇ×Á¦
  • antiamebic drug
    Ç׾Ƹ޹٠¾à
    ¾Æ¸Þ¹Ù¸¦ »ì¸ê ¶Ç´Â ¹ßÀ°À» ¾ïÁ¦ÇÏ´Â ¾à¹°.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • anticancer drug
    Ç×¾ÏÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
drug monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
(12 Dec 1998)
chemotherapeutic Chemotherapeutic agents are those medications that are used to treat various forms of cancer. These medications are given in a particular regimen over a period of weeks. most chemotherapeutic medications have the ability to directly kill cancer cells. For this same reason, these medications can suppress the bone marrow to some degree, lowering white blood cell counts. This results in a condition known as immunosuppression and can place the patient at an increased risk of infection.
Examples include busulphan, cisplatin, cyclophosphamide, methotrexate, daunorubicin, doxorubicin, melphalan, vincristine, vinblastine and chlorambucil.
See: immunosuppressive agents.
(27 Sep 1997)
chemotherapeutic agent Chemotherapeutic agents are those medications that are used to treat various forms of cancer. These medications are given in a particular regimen over a period of weeks. most chemotherapeutic medications have the ability to directly kill cancer cells. For this same reason, these medications can suppress the bone marrow to some degree, lowering white blood cell counts. This results in a condition known as immunosuppression and can place the patient at an increased risk of infection.
Examples include busulphan, cisplatin, cyclophosphamide, methotrexate, daunorubicin, doxorubicin, melphalan, vincristine, vinblastine and chlorambucil.
See: immunosuppressive agents.
(27 Sep 1997)
chemotherapeutic index The ratio of the minimal effective dose of a chemotherapeutic agent to the maximal tolerated dose. Originally used by Ehrlich to express the relative toxicity of a chemotherapeutic agent to a parasite and to its host.
(05 Mar 2000)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
biological monitoring This is the periodic examination of biological specimens for the purposes of monitoring their exposure to or the effects of potentially toxic chemicals to the environment. This is normally done by analysing the amounts of the toxic substances or their metabolites present in body tissues and fluids. The term is also used to mean assessment of the biological status of populations and communities of organisms at risk, in order to protect them and to gain an early warning of possible hazards to human health.
(09 Oct 1997)
blood gas monitoring, transcutaneous The noninvasive measurement or determination of the partial pressure (tension) of oxygen and/or carbon dioxide locally in the capillaries of a tissue by the application to the skin of a special set of electrodes. These electrodes contain photoelectric sensors capable of picking up the specific wavelengths of radiation emitted by oxygenated versus reduced haemoglobin.
(12 Dec 1998)
blood glucose monitoring A way of testing how much glucose (sugar) is in the blood. A drop of blood, usually taken from the fingertip, is placed on the end of a specially coated strip, called a testing strip. The strip has a chemical on it that makes it change colour according to how much glucose is in the blood. A person can tell if the level of glucose is low, high, or normal in one of two ways. The first is by comparing the colour on the end of the strip to a colour chart that is printed on the side of the test strip container. The second is by inserting the strip into a small machine, called a meter, which reads the strip and shows the level of blood glucose in a digital window display. Blood testing is more accurate than urine testing in monitoring blood glucose levels because it shows what the current level of glucose is, rather than what the level was an hour or so previously.
(09 Oct 1997)
blood glucose self-monitoring Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes.
(12 Dec 1998)
blood pressure monitoring, ambulatory Method in which prolonged blood pressure readings are made while the patient undergoes normal daily activities. It allows quantitative analysis of the high blood pressure load over time, can help distinguish between types of hypertension, and can assess the effectiveness of antihypertensive therapy.
(12 Dec 1998)
radiation monitoring The observation, either continuously or at intervals, of the levels of radiation in a given area, generally for the purpose of assuring that they have not exceeded prescribed amounts or, in case of radiation already present in the area, assuring that the levels have returned to those meeting acceptable safety standards.
(12 Dec 1998)
monitoring <investigation> The process of continually checking, observing, recording or testing the operation of some procedure. Monitoring occurs for example during anaesthesia or radiation.
(18 Nov 1997)
monitoring, ambulatory The use of electronic equipment to observe or record physiologic processes while the patient undergoes normal daily activities.
(12 Dec 1998)
monitoring, immunologic Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc.
(12 Dec 1998)
monitoring, intraoperative The constant checking on the state or condition of a patient during the course of a surgical operation (e.g., checking of vital signs).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • radio monitoring
    ÀüÆÄ °¨½Ã
  • chemotherapeutic
    È­ÇÐ ¿ä¹ýÀÇ
  • chemotherapeutic,-tical
    È­ÇÐ ¿ä¹ýÀÇ
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • combination drug
    º¹ÇÕ¾à(2Á¾ ÀÌ»óÀÇ Ç×»ý ¹°Áú µîÀÇ È¥ÇÕ¾à)
  • counter drug
    ÀÇ»çÀÇ Ã³¹æ ¾øÀÌ ÆÇ¸ÅµÇ´Â ¾à
  • drug
    ¾à;¾àÁ¦;¾àǰ;¸¶¾à;~¿¡ ¾àÀ»³Ö´Ù;¸¶Ãë½ÃŰ´Ù;¹°¸®°ÔÇÏ´Ù
  • drug addict
    ¸¶¾à Áßµ¶ÀÚ
  • drug buster
    (¹Ì)¸¶¾à ´Ü¼Ó°ü 
  • drug design
    (¾à)¾àÁ¦ ¼³°è(À¯È¿¼ºÀ» ³ôÀ̱â À§ÇÑ Á¾ÇÕÀû °³¹ß °ËÅä
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • drug pump
    (ÀÇ)¾à ÆßÇÁ(Ç÷°ü ÁÖ»ç¿ë)
  • fertillity drug
    ÀӽŠÃËÁøÁ¦
  • garbage drug
    ¿ªÈ¿°ú¸¦ ÃÊ·¡Çϱ⠽¬¿î ¸¶¾à(Á¢ÂøÁ¦³ª ½Ã³Ê µî)
  • hard drug
    ½À°ü¼º ¸¶¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á